BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spell
read at Endpoints ↗DealPositive
After a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity.
BlossomHill Therapeutics and Latigo have filed to list on Nasdaq, each developing drugs aimed at cancer or pain indications.
Industry observers note that up to six biotech firms are now slated for IPOs this summer, signaling a broader revival of investor interest in the space.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugs”
read at Endpoints ↗85 words · retrieved Jul 17
comments(0)
5-min edit window · permanent after that